Skandinaviska Enskilda Banken Ab (Publ) Bicycle Therapeutics PLC Transaction History
Skandinaviska Enskilda Banken Ab (Publ)
- $20.7 Billion
- Q2 2024
A detailed history of Skandinaviska Enskilda Banken Ab (Publ) transactions in Bicycle Therapeutics PLC stock. As of the latest transaction made, Skandinaviska Enskilda Banken Ab (Publ) holds 42,729 shares of BCYC stock, worth $991,740. This represents 0.0% of its overall portfolio holdings.
Number of Shares
42,729
Previous 42,729
-0.0%
Holding current value
$991,740
Previous $1.06 Million
18.72%
% of portfolio
0.0%
Previous 0.01%
Shares
1 transactions
Others Institutions Holding BCYC
# of Institutions
111Shares Held
40.7MCall Options Held
3.4KPut Options Held
12.4K-
Baker Bros. Advisors LP New York, NY9.4MShares$218 Million2.53% of portfolio
-
Deep Track Capital, LP Greenwich, CT3.49MShares$81 Million2.32% of portfolio
-
Ra Capital Management, L.P. Boston, MA2.25MShares$52.3 Million0.69% of portfolio
-
Fcpm Iii Services B.V. Naarden, P72.12MShares$49.3 Million6.34% of portfolio
-
Armistice Capital, LLC New York, NY1.97MShares$45.8 Million0.52% of portfolio
About BICYCLE THERAPEUTICS plc
- Ticker BCYC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 29,676,100
- Market Cap $689M
- Description
- Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease. The co...